Reuters logo
2 months ago
BRIEF-Aurinia Pharma presents voclosporin remission data
June 16, 2017 / 12:15 PM / 2 months ago

BRIEF-Aurinia Pharma presents voclosporin remission data

June 16 (Reuters) - Aurinia Pharmaceuticals Inc:

* Voclosporin remission data from the phase IIB aura-LV study highlighted at eular 2017

* Aurinia Pharmaceuticals Inc - no unexpected safety signals nor adverse events were observed and voclosporin was generally well-tolerated

* Aurinia Pharmaceuticals - there were no electrolyte changes in treatment groups, mean blood pressure was similar across treatment groups through 48 weeks

* Aurinia Pharmaceuticals - voclosporin treated groups showed statistically significant improvement over control group in speed, rates of complete, partial remission

* Aurinia Pharma- voclosporin treated groups demonstrated statistically significant improvement over control group in speed, rates of complete, partial remission Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below